News briefing: Atomwise partners with Israeli incubator; Bayer collaborates with Veracyte in thyroid cancer
AI player Atomwise has teamed up with the Israeli-based incubator FutuRx to launch a company that will use its platform tech to target a new drug for immuno-oncology.
A2i Therapeutics will tap the Israeli Innovation Authority, the FutuRx investors, and in-kind resources and support provided by Atomwise for the help it needs setting out.
“FutuRx is excited to launch a new bio convergence company jointly with a world leader in AI-based drug discovery,” said Kinneret Savitzky, the CEO of FutuRx. — John Carroll
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.